40
Participants
Start Date
April 30, 2025
Primary Completion Date
February 28, 2027
Study Completion Date
December 31, 2027
ES102
ES102 is administered via intravenous infusion, once every 21 days.
Toripalimab
Toripalimab is administered via intravenous infusion, once every 21 days.
RECRUITING
Beijing Chest Hospital, Capital Medical University, Beijing
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
RECRUITING
Jilin Cancer Hospital, Changchun
NOT_YET_RECRUITING
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital), Jinan
RECRUITING
The First Affiliated Hospital of He'nan University of Science and Technology, Luoyang
RECRUITING
Shanxi Provincial Cancer Hospital, Taiyuan
RECRUITING
Taizhou Hospital, Taizhou
Elpiscience (Suzhou) Biopharma, Ltd.
INDUSTRY